Hikma Pharmaceuticals USA INC. recalls Ramipril Capsules USP
- Published
- 2 Sept 2026
- Units affected
- a) 25,970 bottles; b) 2,384 bottles
- Agency
- FDA
- Country
- United States
The hazard
Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228.
- Brand / company
- Hikma Pharmaceuticals USA INC.
- Codes / lots
- a) Lot #: AC5470A, Exp. Date July 2027 b) Lot #: AC5470B, Exp. Date July 2027
- Distribution
- Nationwide within the United States
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 2 Sept 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.